What question did this study set out to answer?

Assess the efficacy of ONC201 in treating diffuse midline glioma of the pons in children.

November 1, 2025Neuro-OncologyOpen Access

CTP-16. ONC201 (Dordaviprone) in the treatment of Diffuse Midline Glioma of the Pons in children: single center experience from Canada

View Full Paper

Ask AI

Bookmark

Authors

Single center experience reveals ONC201 improves progression free survival in children with DMG-P, indicating potential as an effective treatment.

Assess the efficacy of ONC201 in treating diffuse midline glioma of the pons in children.
Analyzed clinical outcomes of children diagnosed with DMG-P from 2012-2024
Compared patients treated with ONC201 to those receiving standard care
Collected data on mutations and treatment responses
Median progression free survival was 9.05 months with ONC201 versus 4.6 months without (p=0.001)
Median overall survival was 19.2 months for ONC201 versus 8.2 months for non-ONC201 (p=0.002)
66% of ONC201 patients received repeat radiation therapy

Brizini et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Single center experience reveals ONC201 improves progression free survival in children with DMG-P, indicating potential as an effective treatment.